Thyroxine suppression therapy for benign, non-functioning solitary thyroid nodules: A quality-effects meta-analysis

Clinical Medicine and Research

Volumn 8, Issue 3-4, 2010, Pages 150-158

  Yousef, Altayyeb ^a   Clark, Justin ^b   Suhail, A R ^b  

^a MUBARAK AL KABEER HOSPITAL   (Kuwait)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Adverse effects; Clinical efficacy; Levothyroxine suppression; Meta analysis; Solitary thyroid nodules

Indexed keywords

LEVOTHYROXINE; PLACEBO; THYROXINE;

CANCER RISK; DRUG EFFECT; DRUG EFFICACY; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK REDUCTION; SYSTEMATIC REVIEW; THYROID CANCER; THYROID NODULE; UNSPECIFIED SIDE EFFECT;

FEMALE; HUMANS; MALE; REMISSION INDUCTION; RISK FACTORS; THYROID NODULE; THYROXINE;

EID: 78650852770     PISSN: 15394182     EISSN: 15546179     Source Type: Journal    
DOI: 10.3121/cmr.2010.881     Document Type: Review

References (42)

1. Alexander EK, Hurwitz S, Heering JP, Benson CB, Frates MC, Doubilet PM, Cibas ES, Larsen PR, Marqusee E. Natural history of benign solid and cystic thyroid nodules. Ann Intern Med 2003;138:315-318.
2. Ross DS. Thyroid hormone suppressive therapy of sporadic nontoxic goiter. Thyroid 1992;2:263-269.
3. Zelmanovitz F, Genro S, Gross JL. Suppressive therapy with levothyroxine for solitary thyroid nodules: a double-blind controlled clinical study and cumulative meta-analyses. J Clin Endocrinol Metab 1998; 3:3881-885.
4. Castro MR, Caraballo PJ, Morris JC. Effectiveness of thyroid hormone suppressive therapy in benign solitary thyroid nodules: a meta-analysis. J Clin Endocrinol Metab 2002;87:4154-4159.
5. Doi SA, Thalib L. A quality-effects model for meta-analysis. Epidemiology 2008;19:94-100.
6. Bax L, Yu LM, Ikeda N, Tsuruta H, Moons KG. Development and validation of MIX: comprehensive free software for meta-analysis of causal research data. BMC Med Res Methodol 2006;6:50
7. Papini E, Bacci V, Panunzi C, Pacella CM, Fabbrini R, Bizzarri G, Petrucci L, Giammarco V, La Medica P, Masala M, et al. A prospective randomized trial of levothyroxine suppressive therapy for solitary thyroid nodules. Clin Endocrinol (Oxf) 1993;38:507-513.
8. Papini E, Petrucci L, Guglielmi R, Panunzi C, Rinaldi R, Bacci V, Crescenzi A, Nardi F, Fabbrini R, Pacella CM. Long-term changes in nodular goiter: a 5-year prospective randomized trial of levothyroxine suppressive therapy for benign cold thyroid nodules. J Clin Endocrinol Metab 1998;83:780-783.
9. Gharib H, James EM, Charboneau JW, Naessens JM, Offord KP, Gorman CA. Suppressive therapy with levothyroxine for solitary thyroid nodules. A double-blind controlled clinical study. N Engl J Med 1987;317:70-75.
10. Wemeau JL, Caron P, Schvartz C, Schlienger JL, Orgiazzi J, Cousty C, Vlaeminck-Guillem V. Effects of thyroidstimulating hormone suppression with levothyroxine in reducing the volume of solitary thyroid nodules and improving extranodular nonpalpable changes: a randomized, double-blind, placebo-controlled trial by the French Thyroid Research Group. J Clin Endocrinol Metab 2002; 87:4928-4934.
11. Reverter JL, Lucas A, Salinas I, Audi L, Foz M, Sanmarti A. Suppressive therapy with levothyroxine for solitary thyroid nodules. Clin Endocrinol (Oxf) 1992;36:25-28.
12. Lima N, Knobel M, Cavaliere H, Sztejnsznajd C, Tomimori E, Medeiros-Neto G. Levothyroxine suppressive therapy is partially effective in treating patients with benign, solid thyroid nodules and multinodular goiters. Thyroid 1997;7:691-697.
13. Larijani B, Pajouhi M, Bastanhagh MH, Sadjadi A, Sedighi N, Eshraghian MR. Evaluation of suppressive therapy for cold thyroid nodules with levothyroxine: double-blind placebocontrolled clinical trial. Endocr Pract 1999;5:251-256.
14. La Rosa GL, Lupo L, Giuffrida D, Gullo D, Vigneri R, Belfiore A. Levothyroxine and potassium iodide are both effective in treating benign solitary solid cold nodules of the thyroid. Ann Intern Med 1995;122:1-8.
15. Mainini E, Martinelli I, Morandi G, Villa S, Stefani I, Mazzi C. Levothyroxine suppressive therapy for solitary thyroid nodule. J Endocrinol Invest 1995;18:796-769.
16. Sakalauskiene E, Jankuviene D, Musneckiene J. [Results of levothyroxine therapy in thyroid nodules]. [Article in Lithuanian] Medicina (Kaunas) 2002;38:712-719.
17. Koc M, Ersoz HO, Akpinar I, Gogas-Yavuz D, Deyneli O, Akalin S. Effect of low- and high-dose levothyroxine on thyroid nodule volume: a crossover placebo-controlled trial. Clin Endocrinol (Oxf) 2002;57:621-628.
18. Tsai CC, Pei D, Hung YJ, Wang TF, Tsai WC, Yao CY, Hsieh MC, Kuo SW. The effect of thyroxine-suppressive therapy in patients with solitary non-toxic thyroid nodules -- a randomised, double-blind, placebo-controlled study. Int J Clin Pract 2006;60:23-26.
19. Papini E, Guglielmi R, Bizzarri G, Graziano F, Bianchini A, Brufani C, Pacella S, Valle D, Pacella CM. Treatment of benign cold thyroid nodules: a randomized clinical trial of percutaneous laser ablation versus levothyroxine therapy or follow-up. Thyroid 2007;17:229-235.
20. Costante G, Crocetti U, Schifino E, Ludovico O, Capula C, Nicotera M, Arturi F, Filetti S. Slow growth of benign thyroid nodules after menopause: no need for long-term thyroxine suppressive therapy in post-menopausal women. J Endocrinol Invest 2004;27:31-36.
21. Baldini M, Gallazzi M, Orsatti A, Fossati S, Leonardi P, Cantalamessa L. Treatment of benign nodular goitre with mildly suppressive doses of L-thyroxine: effects on bone mineral density and on nodule size. J Intern Med 2002;251:407-414.
22. Cheung PS, Lee JM, Boey JH. Thyroxine suppressive therapy of benign solitary thyroid nodules: a prospective randomized study. World J Surg 1989;13:818-821; discussion 822.
23. Berghout A, Wiersinga WM, Drexhage HA, Smits NJ, Touber JL. Comparison of placebo with L-thyroxine alone or with carbimazole for treatment of sporadic non-toxic goitre. Lancet 1990;336:193-197.
24. Doi SA, Thalib L. An alternative quality adjustor for the quality effects model for meta-analysis. Epidemiology 2009;20:314
25. Al Khalaf MM, Thalib L, Doi SA. Combining heterogenous studies using the random-effects model is a mistake and leads to inconclusive meta-analyses. J Clin Epidemiol 2010 Apr 19 [Epub ahead of print] doi:10.1016/j.jclinepi.2010.01.009.
26. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 1988;318:1728-1733.
27. Walsh JP, Ryan SA, Lisewski D, Alhamoudi MZ, Brown S, Bennedbaek FN, Hegedüs L. Differences between endocrinologists and endocrine surgeons in management of the solitary thyroid nodule. Clin Endocrinol (Oxf) 2007;66:844-853.
28. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Sherman SI, Tuttle RM; American Thyroid Association Guidelines Taskforce. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006;16:109-142.
29. Gharib H, Papini E, Valcavi R, Baskin HJ, Crescenzi A, Dottorini ME, Duick DS, Guglielmi R, Hamilton CR Jr, Zeiger MA, Zini M; AACE/AME Task Force on Thyroid Nodules. American Association of Clinical Endocrinologists and Associazione Medici Endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules. Endocr Pract 2006;12:63-102.
30. Brauer VF, Paschke R. [Pathophysiologic basis for prevention and pharmacotherapy of benign cold thyroid nodules.] [Article in German] Dtsch Med Wochenschr 2003; 128:2324-8.
31. Sdano MT, Falciglia M, Welge JA, Steward DL. Efficacy of thyroid hormone suppression for benign thyroid nodules: meta-analysis of randomized trials. Otolaryngol Head Neck Surg 2005;133:391-396.
32. Richter B, Neises G, Clar C. Pharmacotherapy for thyroid nodules. A systematic review and meta-analysis. Endocrinol Metab Clin North Am 2002;31:699-722.
33. Csako G, Byrd D, Wesley RA, Sarlis NJ, Skarulis MC, Nieman LK, Pucino F. Assessing the effects of thyroid suppression on benign solitary thyroid nodules. A model for using quantitative research synthesis. Medicine (Baltimore) 2000;79:9-26.
34. Fazio S, Biondi B, Carella C, Sabatini D, Cittadini A, Panza N, Lombardi G, Saccà L. Diastolic dysfunction in patients on thyroid-stimulating hormone suppressive therapy with levothyroxine: beneficial effect of beta-blockade. J Clin Endocrinol Metab 1995;80:2222-2226.
35. Faber J, Galloe AM. Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta-analysis. Eur J Endocrinol 1994;130:350-356.
36. Uzzan B, Campos J, Cucherat M, Nony P, Boissel JP, Perret GY. Effects on bone mass of long term treatment with thyroid hormones: a meta-analysis. J Clin Endocrinol Metab 1996;81:4278-4289.
37. Knudsen N, Faber J, Sierbaek-Nielsen A, Vadstrup S, Sorensen HA, Hegedus L. Thyroid hormone treatment aiming at reduced, but not suppressed, serum thyroid-stimulating hormone levels in nontoxic goitre: effects on bone metabolism amongst premenopausal women. J Intern Med 1998;243:149-154.
38. Haentjens P, Van Meerhaeghe A, Poppe K, Velkeniers B. Subclinical thyroid dysfunction and mortality: an estimate of relative and absolute excess all-cause mortality based on time-to-event data from cohort studies. Eur J Endocrinol 2008;159:329-341.
39. Ochs N, Auer R, Bauer DC, Nanchen D, Gussekloo J, Cornuz J, Rodondi N. Meta-analysis: subclinical thyroid dysfunction and the risk for coronary heart disease and mortality. Ann Intern Med 2008;148:832-845.
40. Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, Franklyn JA, Hershman JM, Burman KD, Denke MA, Gorman C, Cooper RS, Weissman NJ. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA 2004;291:228-238.
41. Mazzaferri EL, Young RL, Oertel JE, Kemmerer WT, Page CP. Papillary thyroid carcinoma: the impact of therapy in 576 patients. Medicine (Baltimore) 1977;56:171-196.
42. Hill LD, Beebe HG, Hipp R, Jones HW. Proceedings: Thyroid suppression. Arch Surg 1974;108:403/405.